WASHINGTON TRUST Co increased its position in shares of Becton Dickinson and Co (NYSE:BDX) by 2.2% in the 4th quarter, HoldingsChannel.com reports. The firm owned 95,054 shares of the medical instruments supplier’s stock after acquiring an additional 2,062 shares during the quarter. WASHINGTON TRUST Co’s holdings in Becton Dickinson and were worth $20,347,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Stephens Inc. AR lifted its position in Becton Dickinson and by 3.6% during the fourth quarter. Stephens Inc. AR now owns 7,926 shares of the medical instruments supplier’s stock worth $1,697,000 after purchasing an additional 277 shares during the period. Calton & Associates Inc. bought a new position in shares of Becton Dickinson and in the fourth quarter worth about $203,000. Patten Group Inc. lifted its holdings in shares of Becton Dickinson and by 181.4% in the fourth quarter. Patten Group Inc. now owns 5,777 shares of the medical instruments supplier’s stock worth $1,237,000 after acquiring an additional 3,724 shares during the last quarter. Raymond James Trust N.A. lifted its holdings in shares of Becton Dickinson and by 8.6% in the fourth quarter. Raymond James Trust N.A. now owns 6,411 shares of the medical instruments supplier’s stock worth $1,372,000 after acquiring an additional 505 shares during the last quarter. Finally, Dowling & Yahnke LLC lifted its holdings in shares of Becton Dickinson and by 3.4% in the fourth quarter. Dowling & Yahnke LLC now owns 8,108 shares of the medical instruments supplier’s stock worth $1,736,000 after acquiring an additional 270 shares during the last quarter. 75.68% of the stock is owned by institutional investors and hedge funds.

Becton Dickinson and Co (BDX) opened at $221.92 on Thursday. Becton Dickinson and Co has a 52 week low of $175.66 and a 52 week high of $248.39. The company has a quick ratio of 5.03, a current ratio of 5.58 and a debt-to-equity ratio of 1.44. The stock has a market capitalization of $60,575.49, a P/E ratio of 169.40, a PEG ratio of 1.62 and a beta of 1.12.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings data on Tuesday, February 6th. The medical instruments supplier reported $2.48 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.41 by $0.07. Becton Dickinson and had a return on equity of 19.84% and a net margin of 2.71%. The company had revenue of $3.08 billion during the quarter, compared to the consensus estimate of $3.05 billion. During the same quarter in the prior year, the firm posted $2.33 earnings per share. The firm’s revenue was up 5.4% compared to the same quarter last year. analysts expect that Becton Dickinson and Co will post 10.94 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 30th. Stockholders of record on Friday, March 9th will be paid a $0.75 dividend. This represents a $3.00 annualized dividend and a dividend yield of 1.35%. The ex-dividend date is Thursday, March 8th. Becton Dickinson and’s dividend payout ratio is currently 229.01%.

A number of research analysts have recently commented on BDX shares. Royal Bank of Canada reissued a “hold” rating and issued a $210.00 target price on shares of Becton Dickinson and in a report on Wednesday, October 25th. Zacks Investment Research cut shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a report on Friday, January 5th. Deutsche Bank set a $260.00 target price on shares of Becton Dickinson and and gave the stock a “buy” rating in a report on Friday, December 29th. KeyCorp started coverage on shares of Becton Dickinson and in a report on Friday, January 5th. They issued an “overweight” rating and a $260.00 target price for the company. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $245.00 target price on shares of Becton Dickinson and in a report on Friday, November 3rd. Four analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. Becton Dickinson and has a consensus rating of “Buy” and a consensus target price of $237.27.

COPYRIGHT VIOLATION NOTICE: This article was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://www.dailypolitical.com/2018/02/08/becton-dickinson-and-co-bdx-position-raised-by-washington-trust-co.html.

Becton Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.